Microbial therapeutics: New opportunities for drug delivery

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Miguel, Langer, Robert, Traverso, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504217/
https://www.ncbi.nlm.nih.gov/pubmed/31028093
http://dx.doi.org/10.1084/jem.20190609
_version_ 1783416529587535872
author Jimenez, Miguel
Langer, Robert
Traverso, Giovanni
author_facet Jimenez, Miguel
Langer, Robert
Traverso, Giovanni
author_sort Jimenez, Miguel
collection PubMed
description With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
format Online
Article
Text
id pubmed-6504217
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-65042172019-11-06 Microbial therapeutics: New opportunities for drug delivery Jimenez, Miguel Langer, Robert Traverso, Giovanni J Exp Med News With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics. Rockefeller University Press 2019-05-06 2019-04-26 /pmc/articles/PMC6504217/ /pubmed/31028093 http://dx.doi.org/10.1084/jem.20190609 Text en © 2019 MIT http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle News
Jimenez, Miguel
Langer, Robert
Traverso, Giovanni
Microbial therapeutics: New opportunities for drug delivery
title Microbial therapeutics: New opportunities for drug delivery
title_full Microbial therapeutics: New opportunities for drug delivery
title_fullStr Microbial therapeutics: New opportunities for drug delivery
title_full_unstemmed Microbial therapeutics: New opportunities for drug delivery
title_short Microbial therapeutics: New opportunities for drug delivery
title_sort microbial therapeutics: new opportunities for drug delivery
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504217/
https://www.ncbi.nlm.nih.gov/pubmed/31028093
http://dx.doi.org/10.1084/jem.20190609
work_keys_str_mv AT jimenezmiguel microbialtherapeuticsnewopportunitiesfordrugdelivery
AT langerrobert microbialtherapeuticsnewopportunitiesfordrugdelivery
AT traversogiovanni microbialtherapeuticsnewopportunitiesfordrugdelivery

Ejemplares similares